3-Triazolylmethyl Triazine-2,4-Dione Compounds for 3CLpro Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-coronavirus drugs face challenges in effectively inhibiting the 3CLpro enzyme, a crucial target for coronavirus replication, with issues related to toxicity and efficacy, particularly against mutant strains like Delta and Omicron.
Innovation Solution
Development of 3-triazolylmethyl-1,3,5-triazine-2,4-dione compounds with specific structural modifications that exhibit strong inhibitory activity against 3CLpro, including compounds 1, 7, 12, 15, 16, 17, 18, 22, and 23, which have IC50 values below 200 nM, and compound 1 showing the best activity with an IC50 < 100 nM, along with a method for their synthesis under mild conditions suitable for industrial production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-coronavirus drugs are used to inhibit 3CLpro, then viral replication is suppressed, but cytotoxicity increases and efficacy against mutant strains decreases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of triazine-2,4-dione compounds through varying substituents at different positions (R1-R6 groups). This structural parameter optimization enables the compounds to achieve potent 3CLpro inhibition (IC50 < 200 nM) while maintaining low cytotoxicity, resolving the contradiction between efficacy and safety.
Solution Approach 2:
The patent employs composite material principles by creating complex multi-substituted triazine-2,4-dione structures that combine electron-withdrawing and electron-donating groups. These composite molecular structures enhance binding affinity to 3CLpro while preserving cellular compatibility, achieving both high inhibitory activity and low cytotoxicity simultaneously.
2Reliability
If existing anti-coronavirus drugs are used to inhibit 3CLpro, then viral replication is suppressed, but efficacy against mutant strains (Delta and Omicron) decreases
Solution Approach 1:
The patent utilizes parameter changes by optimizing the substituent patterns on the triazine core to maintain consistent binding to the highly conserved 3CLpro active site across different coronavirus strains. The specific arrangement of R1-R6 groups enables the compounds to effectively inhibit both wild-type and mutant 3CLpro enzymes, demonstrating adaptability to viral mutations.
3Reliability
If complex chemical structures are designed to improve 3CLpro inhibition, then inhibitory activity increases, but manufacturing complexity and cost increase
Solution Approach 1:
The patent applies segmentation by dividing the molecular design into modular components: a core triazine-2,4-dione structure with independently variable substituent groups (R1-R6). This modular approach allows systematic optimization of inhibitory activity while maintaining reasonable synthetic complexity, as each substituent can be introduced through established organic chemistry methods.
Solution Approach 2:
The patent employs universality by designing a platform compound (triazine-2,4-dione core) that serves multiple functions: it provides the essential binding interactions with 3CLpro while allowing diverse substituent variations to optimize different properties (affinity, selectivity, pharmacokinetics). This universal scaffold approach facilitates both high inhibitory activity and manageable manufacturing.
Data Source
AI summary
Disclosed is a compound of formula I, a pharmaceutically acceptable salt, or a tautomer thereof.formula I. R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, methyl group, tert-butyl group, methoxy group, difluoromethyl, trifluoromethyl, trifluoromethoxy, nitro, halogen, phenyl and aromatic heterocyclic; R5 is a hydrogen or halogen; and R6 is hydrogen, C1-4 alkane or C1-4 cycloalkane.